Materialise NV (MTLS)
Materialise NV: My DCF Valuation Indicates Upside Potential
Materialise is rated BUY with a $10 target, offering over 60% upside potential using a DCF with conservative assumptions. MTLS's Medical segment drives growth, offsetting industrial weakness; management focuses on mass personalization in healthcare and cost control. Industrial segment faces cyclical headwinds, but MTLS is shifting toward aerospace/defense and exiting less profitable operations to improve margins.
Materialise: Automotive Weakness Is Undermining The Stock
Materialise's Q2 results were weak due to European automotive headwinds and macro uncertainty. Materialise's Medical segment continues to thrive, and its Software business is nearly done transitioning to a recurring revenue model. Medical segment strength justifies a higher valuation, but the Manufacturing business must stabilize before the stock can meaningfully re-rate.
Materialise NV (MTLS) Q2 2025 Earnings Call Transcript
Materialise NV (NASDAQ:MTLS ) Q2 2025 Earnings Conference Call July 24, 2025 8:30 AM ET Company Participants Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Alexander Craeymeersch - Kepler Cheuvreux, Research Division Troy Donavon Jensen - Cantor Fitzgerald & Co., Research Division Harriet Fried - Unidentified Company Operator Good day, and thank you for standing by. Welcome to the Second Quarter 2025 Materialise NV Financial Results Conference Call.
Materialise Q2 Preview: Anticipating Strong Medical Growth; Initiating With 'Buy'
I rate Materialise a 'buy' with a fair value of $8.83, driven by its unique integrated 3D printing software and hardware solutions. Materialise's strategic focus on software and medical segments strengthens its competitive edge, with medical now 47% of revenue and growing double digits. Recurring software revenue exceeds 80% in its segment, supporting margin expansion, customer retention, and reducing business cyclicality.
Materialise: Medical Segment Continues To Thrive
While Materialise's Q1 results were mixed they exceeded low investor expectations, with the company's Medical segment continuing to excel. Market conditions are likely to remain challenging, but lower energy costs and increased defense spending in Europe could help to offset this. Materialise's Medical segment alone more than justifies its current market capitalization.
Materialise NV (MTLS) Q1 2025 Earnings Call Transcript
Materialise NV (NASDAQ:MTLS ) Q1 2025 Earnings Conference Call April 24, 2025 8:30 AM ET Company Participants Harriet Fried - Alliance Advisors, IR Brigitte de Vet - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Troy Jensen - Cantor Fitzgerald Operator Good day and thank you for standing by. Welcome to the First Quarter 2025 Materialise Financial Results Conference Call.
Materialise: Manufacturing Headwinds Are A Distraction
Materialise: Manufacturing Headwinds Are A Distraction
Materialise NV (MTLS) Q4 2024 Earnings Call Transcript
Materialise NV (NASDAQ:MTLS ) Q4 2024 Earnings Conference Call February 20, 2025 8:30 AM ET Company Participants Harriet Fried - Investor Relations Brigitte de Vet-Veithen - Chief Executive Officer Koen Berges - Chief Financial Officer Conference Call Participants Alexander Craeymeersch - Kepler Cheuvreux Troy Jensen - Cantor Fitzgerald Operator Ladies and gentlemen thank you for standing by. Welcome to the Fourth Quarter 2024 Materialise Financial Results Conference Call.
Materialise (MTLS) Is a Great Choice for 'Trend' Investors, Here's Why
Materialise (MTLS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Should Value Investors Buy Materialise (MTLS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Momentum in Materialise (MTLS) Should Keep going
Materialise (MTLS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Materialise: Strong Q3 Results Despite Ongoing Market Headwinds
Materialise continues to grow on the back of its Medical segment, which is expanding at a rapid pace. Materialise's margins will continue to improve going forward, driven by a combination of revenue mix and economies of scale. The ACTech plant expansion will provide a material tailwind in 2025, although disruptions wrought by its startup are likely to negatively impact fourth quarter revenue.
